Carlsbad, CA – January 9, 2025 – CB Therapeutics, a U.S.-based synthetic biology company
known for its innovative bio-manufacturing solutions, today announced the expansion of its
platform to include ergoline-based compounds. Ergolines—structurally related to alkaloids
naturally found in ergot fungi—hold broad potential in areas ranging from neurological research
and psychiatric applications to treatments for migraines, postpartum hemorrhage, and
Parkinson’s disease. Building on its proven precision fermentation platform, CB Therapeutics
now offers a scalable, eco-conscious pathway for producing these high-value molecules with
unmatched consistency and purity.
While many recognize ergolines through their association with lysergic acid
derivatives—including LSD—this diverse class of compounds has long been investigated for
numerous medical and research applications. Traditional chemical synthesis methods or direct
sourcing from ergot fungi can be dangerous, inefficient, environmentally burdensome, and
difficult to standardize. By contrast, CB Therapeutics utilizes yeast-based precision fermentation
to produce bioidentical ergoline compounds with minimal waste, reduced carbon footprint, and
dependable yields at any scale.
“Our goal is to unlock nature’s most promising compounds in the most
sustainable way,” said Sher Butt, MBA, Chief Executive Officer of CB Therapeutics. “By
adding ergolines to our synthetic biology platform, we’re helping to accelerate research and
commercialization pathways for partners who want to explore or develop new therapies in
neurology, mental health, and beyond.”
“Our precision fermentation platform can deliver consistent, pure compounds for
use in translational research and product development. Our aim is to make these molecules
more accessible and sustainable, ultimately broadening their potential impact.” noted Jacob
Vogan, PhD, Chief Scientific Officer at CB Therapeutics
Key Advantages of CB Therapeutics’ Biosynthesis Platform:
• Sustainable Production: Precision fermentation significantly reduces toxic
byproducts and resource consumption compared to traditional extraction or chemical synthesis
methods.
• Scalability & Consistency: From small research batches to large-scale
manufacturing, the company’s bioreactors and integrated processing systems ensure high
quality precision fermentation batches.
• Broad Application Potential: Beyond psychedelic research (e.g., LSD
derivatives), ergoline-related compounds show promise in treating migraines, supporting
obstetric care, and exploring therapeutic avenues in neurology and psychiatry.
• Partnership Opportunities: CB Therapeutics actively seeks collaborations to
accelerate product development in pharmaceuticals, clinical research, and other emerging
markets worldwide.
For more information on partnership, licensing, or collaboration inquiries, please contact